Atropine-Associated Central Anticholinergic Syndrome during Carotid Artery Stenting: A Case Report.

Save

Acute neurobehavioral deterioration during carotid artery stenting (CAS) requires prompt evaluation for serious neurological complications. We report a patient in their 70s who developed profound hyperactive delirium approximately 15 minutes after receiving prophylactic intravenous atropine (0.25 mg) during CAS. The episode was characterized by severe agitation, bilateral mydriasis, and facial flushing without focal neurological deficits.

Repeated angiography and subsequent neuroimaging showed no evidence of thromboembolism, intracranial hemorrhage, cerebral edema, or cerebral hyperperfusion. Contrast-induced encephalopathy and cerebral hyperperfusion syndrome were considered but were less consistent with the overall clinical, temporal, and radiographic findings. The patient returned to neurological and cognitive baseline approximately 16 hours after symptom onset without specific antidotal treatment.

The close temporal relationship to atropine exposure and characteristic neurobehavioral and autonomic features favored atropine-associated central anticholinergic syndrome, which should be considered in the differential diagnosis of acute neurobehavioral deterioration during CAS.

INTRODUCTION

Carotid artery stenting (CAS) may provoke bradycardia and hypotension through mechanical stimulation of the carotid sinus baroreceptors during balloon angioplasty and stent deployment [1]. Atropine is therefore frequently administered prophylactically or therapeutically to mitigate these hemodynamic disturbances [2,3]. Although generally well tolerated, atropine can cross the blood-brain barrier and may produce central anticholinergic effects ranging from confusion and delirium to severe agitation, hallucinations, and, in extreme cases, coma [4,5].

Such neuropsychiatric reactions have been reported even at therapeutic doses, particularly in older patients [5-7].

Acute neurobehavioral deterioration during or immediately after CAS presents a diagnostic challenge because thromboembolic complications, intracranial hemorrhage, contrast-induced encephalopathy (CIE), and cerebral hyperperfusion syndrome (CHS) must be promptly considered [8,9]. These conditions may share overlapping clinical features with drug-related neuropsychiatric reactions, complicating early diagnosis and management.

We describe an elderly patient who developed abrupt, profound hyperactive delirium shortly after a low prophylactic dose of intravenous atropine during CAS, accompanied by mydriasis and facial flushing but without focal neurological deficits or explanatory abnormalities on neurovascular imaging. This case highlights central anticholinergic syndrome as an uncommon but clinically important consideration when acute neurobehavioral deterioration occurs during CAS.

CASE REPORT

A patient in their 70s was referred for severe right proximal internal carotid artery (ICA) stenosis detected on screening carotid ultrasonography. The patient had mild untreated hypertension but no history of cognitive impairment, dementia, delirium, or psychiatric illness. The patient was fully independent in daily activities and remained occupationally active.

After diagnosis, clopidogrel (75 mg/day), rosuvastatin (10 mg/day), and ezetimibe (10 mg/day) were initiated. Brain magnetic resonance imaging (MRI) showed old lacunar infarctions in the left basal ganglia and corona radiata without recent ischemia. Computed tomography (CT) angiography showed severe right proximal ICA stenosis with predominantly noncalcified plaque, while CT perfusion showed mild ipsilateral perfusion delay with preserved cerebral blood flow and volume.

The patient was neurologically intact before the procedure.

Elective CAS was performed. Angiography demonstrated 85% right ICA stenosis according to the North American Symptomatic Carotid Endarterectomy Trial criteria, with plaque ulceration (Fig. 1A).

Prestenting angioplasty was performed using a Sterling 3×20-mm balloon catheter (Boston Scientific), followed by placement of an Emboshield NAV6 distal embolic protection device (Abbott Vascular). An 8×29-mm Carotid WALLSTENT (Boston Scientific) was then deployed, followed by poststenting angioplasty using an Aviator Plus 5×30-mm balloon catheter (Cordis). Immediately before poststenting angioplasty, prophylactic atropine (0.25 mg intravenously) was administered to attenuate carotid baroreceptor-mediated bradycardia.

No sedative, opioid, or other centrally acting medication had been administered. Completion angiography, performed approximately 6 minutes after atropine administration, demonstrated satisfactory stent expansion with restoration of the ICA lumen (Fig. 1B) and preserved intracranial circulation.

Immediately thereafter, the patient communicated normally and showed no focal neurological abnormalities.

Approximately 15 minutes after atropine administration, immediately after the first delayed angiographic run, the patient developed impaired attention and responsiveness. Although the patient remained calm, responded slowly to simple questions, required repeated questioning, and made poor eye contact. With repeated prompting, no focal neurological deficit was apparent.

Because an embolic complication was suspected, repeat intracranial angiography was planned. Within several minutes, however, the patient developed profound psychomotor agitation and combative behavior. The patient abruptly attempted to sit upright on the angiography table, struggled violently with all 4 extremities, and repeatedly tried to break free from the restraints, nearly falling from the table and placing the femoral arterial sheath at risk of dislodgement.

The patient became verbally aggressive, shouting profanities and repeatedly demanding to be released. Despite the extreme agitation, patient’s speech remained clear and fluent without aphasia or dysarthria, and all 4 extremities moved vigorously and symmetrically without weakness. No gaze deviation, extraocular movement abnormality, facial palsy, or seizure activity was observed, and patient did not complain of headache.

Both pupils were dilated to approximately 7 mm and sluggishly reactive to light; facial flushing was also noted.

Intravenous midazolam (10 mg) and lorazepam (4 mg) failed to achieve meaningful sedation, whereas subsequent haloperidol (1 mg) provided adequate behavioral control. Repeat intracranial angiography showed patent intracranial arteries without thromboembolic occlusion or other acute abnormalities (Fig. 1C); additional delayed and contralateral angiographic runs were also unremarkable.

The total volume of iohexol contrast medium (270 mg iodine/mL; Iobrix Inj. 270, Taejoon Pharm) was estimated at 150 mL. Immediate cone-beam CT showed no intracranial hemorrhage, cerebral edema, or abnormal contrast staining (Fig.

1D), and postprocedural brain MRI showed no acute infarction, hemorrhage, or other explanatory lesion (Fig. 1E). The patient was transferred to the intensive care unit under pharmacological sedation.

Severe agitation recurred as the initial sedation waned. Approximately 3 hours after symptom onset, a continuous dexmedetomidine infusion was initiated, with intermittent haloperidol for breakthrough agitation. No specific antidote, including physostigmine, was administered.

Adequate pharmacological sedation was achieved, with a Glasgow Coma Scale score of 7. Follow-up CT with CT perfusion approximately 6 hours after symptom onset showed no hemorrhage, cerebral edema, abnormal contrast staining, or cerebral hyperperfusion (Fig. 1F).

Progressive bradycardia to approximately 40 beats/min during dexmedetomidine infusion necessitated gradual dose reduction.

As dexmedetomidine was reduced and sedation wore off, recurrence of severe agitation was anticipated. However, approximately 16 hours after symptom onset, the patient awoke fully oriented and able to follow commands appropriately, without behavioral abnormalities or focal neurological deficits. The patient’s neurological and cognitive status remained normal thereafter.

The patient subsequently reported complete amnesia from approximately the middle of the procedure until awakening in the intensive care unit. Follow-up carotid ultrasonography showed a patent stent without significant residual stenosis. The patient was transferred to the general ward on postoperative day 2 and discharged home on postoperative day 4, having returned to preprocedural neurological and cognitive baseline.

DISCUSSION

The present case illustrates a rare and diagnostically challenging presentation of acute neurobehavioral deterioration during CAS. Several features collectively favored a diagnosis of atropine-associated central anticholinergic syndrome: the close temporal relationship between atropine administration and symptom onset, evolution from impaired attention to profound hyperactive delirium, accompanying mydriasis and facial flushing, absence of focal neurological deficits, and complete recovery without neurological sequelae. Importantly, no sedative, opioid, or other centrally acting medication had been administered before symptom onset, reducing the likelihood of a confounding drug effect.

Repeated angiography and subsequent neuroimaging showed no evidence of procedural thromboembolism or intracranial hemorrhage. Nevertheless, because atropine administration coincided with both intra-arterial contrast exposure and carotid revascularization, CIE and CHS required careful consideration (Table 1).

Central anticholinergic syndrome results from muscarinic cholinergic blockade within the central nervous system. Acetylcholine has important roles in arousal, attention, orientation, memory, and the sleep-wake cycle; consequently, central cholinergic inhibition may produce a broad spectrum of manifestations ranging from agitation, delirium, hallucinations, and seizures to somnolence, stupor, and coma [4]. As a lipophilic tertiary amine, atropine can cross the blood-brain barrier and exert central anticholinergic effects [4].

Peripheral manifestations may include mydriasis, flushing, tachycardia, decreased secretions, and urinary retention, but their absence does not exclude the syndrome [4,7]. In our patient, the combination of marked hyperactive delirium, bilateral mydriasis, and facial flushing was therefore compatible with both central and peripheral anticholinergic effects.

Although central anticholinergic syndrome is more commonly associated with larger anticholinergic exposures, clinically significant neuropsychiatric reactions have been reported with therapeutic doses of atropine. Postoperative delirium has been described after intravenous atropine doses as low as 0.2–0.6 mg [5], and central anticholinergic manifestations have also been reported after therapeutic topical atropine in older patients [6]. These observations are relevant to our patient, who developed symptoms after only 0.25 mg of intravenous atropine, and suggest that clinically significant central anticholinergic effects may occur even at low therapeutic doses, particularly in susceptible older patients [7].

The prophylactic atropine dose used in our patient was lower than the 0.5–1 mg doses commonly reported during CAS [2]. However, the anticipated baroreflex response may vary according to lesion location; baroreceptor reactions have been reported less frequently with apical than with body lesions of the carotid bulb [10]. In our patient, the maximal stenosis was located relatively distal to the carotid bulb, and a pronounced baroreflex response was considered less likely.

A reduced prophylactic dose of atropine was therefore selected based on this anatomical consideration. Notably, atropine doses ranging from 0.25 to 1 mg have been reported during CAS [10].

The temporal sequence provides additional support for this interpretation. Approximately 6 minutes after atropine administration, completion angiography and neurological examination were normal. Subtle impairment of attention and responsiveness appeared approximately 15 minutes after administration and rapidly evolved into severe psychomotor agitation.

The subsequent return to normal cognition without recurrence also suggests the possibility of a transient drug-related syndrome. Although the approximately 16-hour interval to confirmed recovery was longer than the reported atropine elimination half-life of approximately 2 hours, the duration of clinical effects, particularly central nervous system effects, does not necessarily parallel plasma elimination and may be considerably longer [11]. Moreover, because neurological assessment during the intervening period was limited by pharmacological sedation, complete cognitive recovery may have occurred earlier than the time at which it was first confirmed.

Management of central anticholinergic syndrome is primarily supportive, including withdrawal of the offending agent, close monitoring, and control of severe agitation [4,7]. Physostigmine, a centrally acting acetylcholinesterase inhibitor, may be considered for severe or persistent anticholinergic delirium because it can reverse central anticholinergic manifestations [4,7,12]. Earlier regimens often used 1–2 mg of intravenous physostigmine as an initial dose, with additional doses given at relatively short intervals; however, more conservative titration has been advocated because such rapid dosing may result in excessive cholinergic effects.

Accordingly, cautious intravenous titration with 0.5–1 mg, followed by clinical reassessment for at least 10–15 minutes before additional dosing, has been proposed [12]. Careful patient selection and cardiac monitoring are warranted because cholinergic adverse effects, including bradycardia and seizures, may occur [12].

CIE was the most important competing diagnosis because approximately 150 mL of iohexol was administered intra-arterially. CIE is a rare complication of endovascular procedures attributed to transient blood-brain barrier disruption and contrast neurotoxicity, typically manifesting within minutes to hours after contrast exposure. Reported features include encephalopathy, cortical blindness, seizures, aphasia, and focal neurological deficits [13,14].

CIE has specifically been reported after CAS, including a case in which a patient who received atropine during the procedure subsequently developed stupor, aphasia, and hemiparesis with ipsilateral cortical contrast staining, a clinical and radiographic pattern consistent with CIE [8]. Importantly, normal CT or MRI findings do not exclude CIE, as neuroimaging may remain unremarkable in a substantial proportion of patients [13]. Nevertheless, our patient’s presentation was less typical of CIE: it was predominantly hyperactive, without aphasia, seizures, or lateralizing neurological deficits, and serial imaging showed no cerebral edema or characteristic cortical or subarachnoid contrast staining.

Thus, although CIE could not be completely excluded, the overall clinical and radiographic pattern was less consistent with CIE than with an atropine-associated central anticholinergic syndrome.

CHS was another important competing diagnosis after restoration of flow through a severe ICA stenosis. CHS is thought to result from impaired cerebrovascular autoregulation in chronically hypoperfused brain tissue, leading to excessive cerebral blood flow after revascularization and potentially causing vasogenic edema, seizures, or intracranial hemorrhage [15,16]. Although altered consciousness or confusion may occur, CHS typically develops several hours to days after revascularization and is commonly associated with headache, seizures, focal neurological deficits, or objective evidence of cerebral hyperperfusion or reperfusion injury [16,17].

Importantly, early-onset CHS can occur, and the absence of conventional structural imaging abnormalities does not by itself exclude the diagnosis [15]. Nevertheless, the predominantly hyperactive neurobehavioral syndrome in our patient developed approximately 15 minutes after atropine administration, substantially earlier than the typical onset of CHS, without headache, seizures, or focal neurological deficits. Moreover, follow-up CT perfusion demonstrated no cerebral hyperperfusion, further reducing the likelihood of CHS.

Thus, although an atypical early presentation could not be completely excluded, the overall temporal, clinical, and perfusion pattern was less consistent with CHS than with an atropine-associated central anticholinergic syndrome.

Several limitations preclude definitive attribution to atropine. Central anticholinergic syndrome is primarily a clinical diagnosis, and no serum atropine concentration was obtained. Physostigmine, which can cross the blood-brain barrier and may reverse central anticholinergic manifestations, was not administered; therefore, pharmacological reversal could not be used as supportive diagnostic evidence [4,7].

Moreover, the simultaneous exposures inherent to CAS—atropine, iodinated contrast, and abrupt cerebral reperfusion—create unavoidable diagnostic overlap. Thus, our observations establish a strong temporal and phenotypic association rather than definitive causality.

Despite these limitations, this case emphasizes that atropine-associated central anticholinergic syndrome should be included in the differential diagnosis of acute neurobehavioral deterioration during CAS, even after a relatively low prophylactic dose. Recognition is particularly important because its presentation may closely mimic serious neurological complications that demand immediate investigation. Prompt evaluation for ischemic or hemorrhagic complications, CIE, and CHS remains essential; when these evaluations are unrevealing, the timing of drug exposure and the characteristic neurobehavioral and autonomic features may provide important diagnostic clues.

Related articles

PubMed

Correction: STudy of Atropine to Reduce (STAR) Myopia Progression in Children: 24-Month Results of a Randomized, Double-Masked, Vehicle-Controlled Trial of Atropine Sulfate 0.01% and 0.03.

Correction: Ophthalmology and Therapy (2026) 15:1685–1703https://doi.org/10.1007/s40123-026-01341-0 In this article, in the PLAIN LANGUAGE SUMMARY section, a sentence was incorrect which previously appeared as“Children receiving atropine 0.01% had 0.13 diopters less myopia worsening at 2 years than those receiving vehicle, while those using atropine 0.03% had 0.12 diopters less worsening.” But should have been“Children receiving atropine 0.01% had 0.13D/year less myopia worsening at two years...

PubMed

Efficacy of Combined Highly Aspherical Lenslet Target (HALT) Spectacles and Low-Dose Atropine in Children with Poor Response to Atropine Monotherapy over 24 Months.

Objectives: To evaluate the 24-month efficacy of combining highly aspherical lenslet target (HALT) spectacle lenses with low-dose atropine (LDA) in children with poor response to atropine monotherapy. Methods: This prospective interventional cohort study included myopic children aged 6–11 years who continued to progress despite LDA (0.01–0.025%). Fifty children completed 12 months of follow-up and 48 completed 24 months. At 12 months, atropine dosage was maintained, reduced, or increased accordi...